Latest Gilead Sciences (GILD) Headlines Jim Cra
Post# of 162
Posted On: 03/13/2014 8:57:56 AM
Latest Gilead Sciences (GILD) Headlines
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
Can Gilead Dominate The HIV Drug Market Again in 2014?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 12, 5:35PM CDT
Gilead's slate of HIV drug therapies helped it capture the bulk of the market in 2013, outpacing competing therapies from Johnson & Johnson and Bristol-Myers . Sales from Gilead's HIV drugs totaled more than $9 billion last year,...
Sanofi, UCB Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:10PM CDT
Sanofi entered into an agreement with UCB for the discovery and development of therapies for immune-mediated diseases including gastroenterology and arthritis.
Final Glance: Biotechnology companies
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Midday Glance: Biotechnology companies
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Gilead Sciences' (GILD) Hep C Treatment Receives 'Low Value' Rating
at The Street - Wed Mar 12, 12:05PM CDT
Shares of Gilead Sciences are are up today by $0.21 (0.26%) as of 12:14:13 PM EST despite news of a "low value" rating given to Gilead's hepatitis C drug treatment Sovaldi from the influential California Technology Assessment.
Early Glance: Biotechnology companies
AP - Wed Mar 12, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Gilead Sciences (GILD) Approaches New Downside Target of $78.66
Comtex SmarTrend(R) - Wed Mar 12, 9:07AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $79.91 today and has reached the first level of support at $79.25. Investors may be interested in a cross of the next downside pivot targets of $78.66 and $77.41.
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Focus on Regulus' Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 6:00PM CDT
Regulus is working hard to develop its pipeline.
Medical groups question price of new hep C drug
By MATTHEW PERRONE - AP - Tue Mar 11, 1:18PM CDT
WASHINGTON (AP) — An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc.
Alexion Lifts 2014 View, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 12:42PM CDT
Alexion lifts outlook following French reimbursement deal on Soliris.
Stock Market News for March 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:06AM CDT
Benchmarks finished Monday’s trading session nearly flat after recovering from day’s initial losses caused due to a drop in China’s export data and less-than-expected growth in Japan’s economy
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
Can Gilead Dominate The HIV Drug Market Again in 2014?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 12, 5:35PM CDT
Gilead's slate of HIV drug therapies helped it capture the bulk of the market in 2013, outpacing competing therapies from Johnson & Johnson and Bristol-Myers . Sales from Gilead's HIV drugs totaled more than $9 billion last year,...
Sanofi, UCB Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:10PM CDT
Sanofi entered into an agreement with UCB for the discovery and development of therapies for immune-mediated diseases including gastroenterology and arthritis.
Final Glance: Biotechnology companies
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Midday Glance: Biotechnology companies
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Gilead Sciences' (GILD) Hep C Treatment Receives 'Low Value' Rating
at The Street - Wed Mar 12, 12:05PM CDT
Shares of Gilead Sciences are are up today by $0.21 (0.26%) as of 12:14:13 PM EST despite news of a "low value" rating given to Gilead's hepatitis C drug treatment Sovaldi from the influential California Technology Assessment.
Early Glance: Biotechnology companies
AP - Wed Mar 12, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Gilead Sciences (GILD) Approaches New Downside Target of $78.66
Comtex SmarTrend(R) - Wed Mar 12, 9:07AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $79.91 today and has reached the first level of support at $79.25. Investors may be interested in a cross of the next downside pivot targets of $78.66 and $77.41.
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Focus on Regulus' Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 6:00PM CDT
Regulus is working hard to develop its pipeline.
Medical groups question price of new hep C drug
By MATTHEW PERRONE - AP - Tue Mar 11, 1:18PM CDT
WASHINGTON (AP) — An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc.
Alexion Lifts 2014 View, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 12:42PM CDT
Alexion lifts outlook following French reimbursement deal on Soliris.
Stock Market News for March 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:06AM CDT
Benchmarks finished Monday’s trading session nearly flat after recovering from day’s initial losses caused due to a drop in China’s export data and less-than-expected growth in Japan’s economy
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
(0)
(0)